Tofacitinib for refractory ocular mucous membrane pemphigoid

Article Properties
Cite
James, Hayley, et al. “Tofacitinib for Refractory Ocular Mucous Membrane Pemphigoid”. American Journal of Ophthalmology Case Reports, vol. 22, 2021, p. 101104, https://doi.org/10.1016/j.ajoc.2021.101104.
James, H., Paley, G. L., Brasington, R., Custer, P. L., Margolis, T. P., & Paley, M. A. (2021). Tofacitinib for refractory ocular mucous membrane pemphigoid. American Journal of Ophthalmology Case Reports, 22, 101104. https://doi.org/10.1016/j.ajoc.2021.101104
James, Hayley, Grace L. Paley, Richard Brasington, Philip L. Custer, Todd P. Margolis, and Michael A. Paley. “Tofacitinib for Refractory Ocular Mucous Membrane Pemphigoid”. American Journal of Ophthalmology Case Reports 22 (2021): 101104. https://doi.org/10.1016/j.ajoc.2021.101104.
James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA. Tofacitinib for refractory ocular mucous membrane pemphigoid. American Journal of Ophthalmology Case Reports. 2021;22:101104.
Refrences
Title Journal Journal Categories Citations Publication Date
JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis Clinical Rheumatology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the musculoskeletal system
 77 2020
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy JAMA
  • Medicine: Medicine (General)
  • Medicine: Internal medicine
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 201 2019
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

 Arthritis & Rheumatology
  • Medicine
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the musculoskeletal system
  • Medicine: Medicine (General)
 278 2019
Clinical significance of Janus Kinase inhibitor selectivity Rheumatology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the musculoskeletal system
 169 2019
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis Ocular Immunology and Inflammation
  • Medicine: Medicine (General)
  • Medicine: Ophthalmology
 53 2019
Refrences Analysis
Category Category Repetition
Medicine: Medicine (General)23
Medicine: Ophthalmology6
Medicine: Internal medicine5
Medicine4
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the musculoskeletal system3
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy1
Medicine: Therapeutics. Pharmacology1
Science: Chemistry: Analytical chemistry1
Science: Chemistry1
The category Medicine: Medicine (General) 23 is the most frequently represented among the references in this article. It primarily includes studies from New England Journal of Medicine and Ophthalmology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
Title Journal Journal Categories Citations Publication Date
Tofacitinib for the treatment of severe rare skin diseases: a narrative review European Journal of Clinical Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 2024
Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report Patient Preference and Adherence
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 2024
Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches Clinical Reviews in Allergy & Immunology
  • Medicine: Internal medicine: Infectious and parasitic diseases
  • Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
  • Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
  • Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
 2023
Autoimmune blistering diseases: promising agents in clinical trials Expert Opinion on Investigational Drugs
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Therapeutics. Pharmacology
 2023
Abrocitinib‐A promising option for patients with refractory bullous pemphigoid Journal of the European Academy of Dermatology and Venereology
  • Medicine: Medicine (General)
  • Medicine: Dermatology
 1 2023
Citations Analysis
Category Category Repetition
Medicine: Medicine (General)5
Medicine: Dermatology4
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy2
Medicine: Public aspects of medicine: Toxicology. Poisons2
Medicine: Therapeutics. Pharmacology2
Medicine2
Medicine: Internal medicine: Infectious and parasitic diseases1
The category Medicine: Medicine (General) 5 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Multiple drugs and was published in 2021. The most recent citation comes from a 2024 study titled Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report. This article reached its peak citation in 2023, with 4 citations. It has been cited in 9 different journals, 33% of which are open access. Among related journals, the Acta Dermato-Venereologica cited this research the most, with 2 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year